| Clinicopathological parameters | Values |
| Age (years); Mean ± SD | 52.18 ± 12.19 | Age groups | ≤35 years, n (%) | 16 (11.4) | 36–50 years, n (%) | 52 (37.1) | >50 years, n (%) | 72 (51.4) | Follow up duration (months); Mean ± SD | 4.14 ± 1.88 | Tumor laterality | Right breast, n (%) | 78 (55.7) | Left breast, n (%) | 62 (44.3) | Type of biopsy | Trucut, n (%) | 48 (34.3) | Modified radical mastectomy, n (%) | 40 (28.6) | Breast conversion surgery, n (%) | 22 (15.7) | Simple mastectomy, n (%) | 30 (21.4) | Tumor size (cm), n = 92; Mean ± SD | 5.99 ± 3.44 | Tumor (T) stage, n = 92 | T1, n (%) | 12 (13) | T2, n (%) | 34 (37) | T3, n (%) | 46 (50) | Tumor grade | Grade 2, n (%) | 34 (24.3) | Grade 3, n (%) | 106 (75.7) | Squamous differentiation | Present, n (%) | 96 (68.6) | Absent, n (%) | 44 (31.4) | Chondroid differentiation | Present, n (%) | 8 (5.7) | Absent, n (%) | 132 (94.3) | Spindle cell differentiation | Present, n (%) | 16 (11.4) | Absent, n (%) | 124 (88.6) | Nodal (N) stage, n = 92 | N0, n (%) | 52 (56.5) | N1, n (%) | 18 (19.6) | N2, n (%) | 9 (9.8) | N3, n (%) | 13 (14.1) | Recurrence | Yes, n (%) | 44 (31.4) | No, n (%) | 96 (68.6) | Survival status | Alive, n (%) | 100 (71.4) | Expired, n (%) | 40 (28.6) | ER/PR | Positive, n (%) | 46 (32.9) | HER2/neu | Positive, n (%) | 32 (22.9) | Negative, n (%) | 108 (77.1) |
|
|